You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEchothiophate
Accession NumberDB01057  (APRD00942)
TypeSmall Molecule
GroupsApproved
DescriptionA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Structure
Thumb
Synonyms
2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide
Echothiophate
Ecothiopatum
Phospholine
External Identifiers
  • MI 217
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phospholine Iodide - Liq Pws 3mg/5mlLiquid; Powder, for solution3 mgOphthalmicStorz, Division Of Wyeth Ayerst Canada Inc.1997-04-291999-08-12Canada
Phospholine Iodide - Pws 12.5mg/5mlPowder, for solution12.5 mgOphthalmicStorz, Division Of Wyeth Ayerst Canada Inc.1997-08-291999-08-12Canada
Phospholine Iodide - Pws 6.25mg/5mlPowder, for solution6.25 mgOphthalmicStorz, Division Of Wyeth Ayerst Canada Inc.1997-04-292000-08-02Canada
Phospholine Iodide 12.5mg/5mlPowder, for solution12.5 mgOphthalmicWyeth Ayerst Canada Inc.1994-12-312001-08-30Canada
Phospholine Iodide 3mg/5mlPowder, for solution3 mgOphthalmicWyeth Ayerst Canada Inc.1998-12-022001-05-07Canada
Phospholine Iodide 6.25mg/5mlPowder, for solution6.25 mgOphthalmicWyeth Ayerst Canada Inc.1999-10-062001-08-03Canada
Phospholine Iodide OphthalmicKitWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.1959-12-04Not applicableUs
Phospholine Iodide Pws 6.25mg/5mlPowder, for solution6.25 mgOphthalmicWyeth Ayerst Canada Inc.1994-12-311997-08-14Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EchodideAlcon
Phospholine IodideWyeth-Ayerst
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Echothiophate iodide
513-10-0
Thumb
  • InChI Key: OVXQHPWHMXOFRD-UHFFFAOYSA-M
  • Monoisotopic Mass: 383.0181
  • Average Mass: 383.23
DBSALT001098
Categories
UNII0F350BVT6S
CAS number6736-03-4
WeightAverage: 256.323
Monoisotopic: 256.113625809
Chemical FormulaC9H23NO3PS
InChI KeyBJOLKYGKSZKIGU-UHFFFAOYSA-N
InChI
InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1
IUPAC Name
diethyl {[2-(trimethylazaniumyl)ethyl]sulfanyl}phosphonate
SMILES
CCOP(=O)(OCC)SCC[N+](C)(C)C
Pharmacology
IndicationFor use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.
Structured Indications
PharmacodynamicsEchothiophate Iodide is a potent, long-acting cholinesterase inhibitor used as a miotic in the treatment of glaucoma. Echothiophate iodide will depress both plasma and erythrocyte cholinesterase levels in most patients after a few weeks of eyedrop therapy.
Mechanism of actionEchothiophate Iodide is a long-acting cholinesterase inhibitor for topical use which enhances the effect of endogenously liberated acetylcholine in iris, ciliary muscle, and other parasympathetically innervated structures of the eye. Echothiophate iodide binds irreversibly to cholinesterase, and is long acting due to the slow rate of hydrolysis by cholinesterase. It causes miosis, increase in facility of outflow of aqueous humor, fall in intraocular pressure, and potentiation of accommodation.
TargetKindPharmacological actionActionsOrganismUniProt ID
CholinesteraseProteinyes
inhibitor
HumanP06276 details
Related Articles
AbsorptionThis ophthalmic medication may be systemically absorbed.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include blurred vision or change in near or distant vision and eye pain. LD50: 174 mcg/kg in rats. (MSDS)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Echothiophate.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Echothiophate.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Echothiophate.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Echothiophate.Experimental, Illicit
AcebutololEchothiophate may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Echothiophate.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Echothiophate.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Echothiophate.Experimental
AlprenololEchothiophate may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Echothiophate.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Echothiophate.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Echothiophate.Approved
Aop200704Echothiophate may increase the bradycardic activities of Aop200704.Investigational
ArecolineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Arecoline.Experimental
ArotinololEchothiophate may increase the bradycardic activities of Arotinolol.Approved
AtenololEchothiophate may increase the bradycardic activities of Atenolol.Approved
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Echothiophate.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Echothiophate.Approved, Vet Approved
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Echothiophate.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Echothiophate.Approved, Investigational
BefunololEchothiophate may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Echothiophate.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Echothiophate.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Echothiophate.Approved, Vet Approved
BetaxololEchothiophate may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Echothiophate is combined with Bethanechol.Approved
BevantololEchothiophate may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Echothiophate.Approved
BisoprololEchothiophate may increase the bradycardic activities of Bisoprolol.Approved
BopindololEchothiophate may increase the bradycardic activities of Bopindolol.Approved
BucindololEchothiophate may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Echothiophate.Approved
BufuralolEchothiophate may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololEchothiophate may increase the bradycardic activities of Bupranolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Echothiophate is combined with Carbachol.Approved
CarteololEchothiophate may increase the bradycardic activities of Carteolol.Approved
CarvedilolEchothiophate may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololEchothiophate may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Echothiophate.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Echothiophate.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Echothiophate.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Echothiophate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Echothiophate.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Echothiophate.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Echothiophate.Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Echothiophate.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Echothiophate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Echothiophate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Echothiophate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Echothiophate.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Echothiophate.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Echothiophate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Echothiophate.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Echothiophate.Approved
DipyridamoleThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole.Approved
EPIBATIDINEThe risk or severity of adverse effects can be increased when Echothiophate is combined with EPIBATIDINE.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Echothiophate.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Echothiophate.Approved
EsmololEchothiophate may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Echothiophate.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Echothiophate.Approved
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Echothiophate.Approved
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Echothiophate.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Echothiophate.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Echothiophate.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Echothiophate.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Echothiophate.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Echothiophate.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Echothiophate.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Echothiophate.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Echothiophate.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Echothiophate.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Echothiophate.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Echothiophate.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Echothiophate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Echothiophate.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Echothiophate.Approved, Investigational, Withdrawn
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Echothiophate.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Echothiophate.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Echothiophate is combined with GTS-21.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Echothiophate.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Echothiophate.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Echothiophate.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Echothiophate.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Echothiophate.Approved
IndenololEchothiophate may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Echothiophate.Investigational
LabetalolEchothiophate may increase the bradycardic activities of Labetalol.Approved
LevobunololEchothiophate may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Lobeline.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Echothiophate.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Echothiophate.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Echothiophate.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Echothiophate.Vet Approved
MethacholineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Methacholine.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Echothiophate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Echothiophate.Approved, Vet Approved
MetipranololEchothiophate may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Echothiophate.Approved
MetoprololEchothiophate may increase the bradycardic activities of Metoprolol.Approved, Investigational
MivacuriumEchothiophate may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate.Approved, Vet Approved
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Echothiophate.Vet Approved
NadololEchothiophate may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Echothiophate.Investigational
NicotineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Echothiophate is combined with Nicotine bitartrate.Approved
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Echothiophate.Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Echothiophate.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Echothiophate.Approved
OxprenololEchothiophate may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Echothiophate.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Echothiophate.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Echothiophate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Echothiophate.Approved
PenbutololEchothiophate may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Echothiophate.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Pilocarpine.Approved
PindololEchothiophate may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Echothiophate.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Echothiophate.Approved
PractololEchothiophate may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Echothiophate.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Echothiophate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Echothiophate.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Echothiophate.Experimental
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Echothiophate.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Echothiophate.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Echothiophate.Investigational
PropranololEchothiophate may increase the bradycardic activities of Propranolol.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Echothiophate.Approved
RapacuroniumEchothiophate may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Echothiophate.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Echothiophate.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Echothiophate.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Echothiophate.Approved
SotalolEchothiophate may increase the bradycardic activities of Sotalol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Echothiophate.Approved
TimololEchothiophate may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Echothiophate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Echothiophate.Approved
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Echothiophate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Echothiophate.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Echothiophate.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Echothiophate.Approved
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Echothiophate.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Echothiophate.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Echothiophate.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Echothiophate.Approved
VareniclineThe risk or severity of adverse effects can be increased when Echothiophate is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate.Approved
Food InteractionsNot Available
References
Synthesis Reference

Fitch, H.M.; U.S. Patent 2,911,430; November 3, 1959; assigned to Campbell Pharmaceuticals, Inc.

General References
  1. Reddy RH: Echothiophate iodide: its use in accommodative esotropia (high Ac/A ratio). Indian J Ophthalmol. 1982 Jul;30(4):225. [PubMed:7166393 ]
  2. Schmidt KG, Horowitz Y, Buckman G, Segev E, Levinger E, Geyer O: Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma. Curr Eye Res. 2010 Aug;35(8):698-702. doi: 10.3109/02713681003794076. [PubMed:20673046 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (45 KB)
MSDSDownload (87.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7708
Blood Brain Barrier+0.91
Caco-2 permeable+0.5098
P-glycoprotein substrateNon-substrate0.6063
P-glycoprotein inhibitor INon-inhibitor0.8482
P-glycoprotein inhibitor IINon-inhibitor0.962
Renal organic cation transporterNon-inhibitor0.7835
CYP450 2C9 substrateNon-substrate0.8237
CYP450 2D6 substrateNon-substrate0.7603
CYP450 3A4 substrateNon-substrate0.5252
CYP450 1A2 substrateNon-inhibitor0.8317
CYP450 2C9 inhibitorNon-inhibitor0.7972
CYP450 2D6 inhibitorNon-inhibitor0.8991
CYP450 2C19 inhibitorNon-inhibitor0.8013
CYP450 3A4 inhibitorNon-inhibitor0.9093
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9377
Ames testNon AMES toxic0.8524
CarcinogenicityCarcinogens 0.7021
BiodegradationReady biodegradable0.9528
Rat acute toxicity4.3595 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5816
hERG inhibition (predictor II)Non-inhibitor0.7263
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Liquid; powder, for solutionOphthalmic3 mg
Powder, for solutionOphthalmic12.5 mg
Powder, for solutionOphthalmic3 mg
Kit
Powder, for solutionOphthalmic6.25 mg
Prices
Unit descriptionCostUnit
Phospholine iodide 0.125%16.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US2911430 No1958-01-151978-01-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point124-124.5Fitch, H.M.; U.S. Patent 2,911,430; November 3, 1959; assigned to Campbell Pharmaceuticals, Inc.
water solubilitySolubleNot Available
logP-2.25Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.297 mg/mLALOGPS
logP-2.1ALOGPS
logP-3.1ChemAxon
logS-3ALOGPS
pKa (Strongest Basic)-8.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity78.14 m3·mol-1ChemAxon
Polarizability27.65 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quaternary ammonium salts. These are compounds containing positively charged polyatomic ion of the structure NR4+, R being an alkyl group or an aryl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassQuaternary ammonium salts
Sub ClassNot Available
Direct ParentQuaternary ammonium salts
Alternative Parents
Substituents
  • Quaternary ammonium salt
  • Sulfenyl compound
  • Organothiophosphorus compound
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Amine
  • Organic cation
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Henderson EG, Post-Munson DJ, Reynolds LS, Epstein PM: Echothiophate and cogeners decrease the voltage dependence of end-plate current decay in frog skeletal muscle. J Pharmacol Exp Ther. 1989 Dec;251(3):810-6. [PubMed:2481033 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:46